Unfreezing the ICER: Implications of the UK’s Landmark Decision to Raise NICE Cost-Effectiveness Thresholds
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
$2995
In December 2025, the UK National Institute for Health and Care Excellence (NICE) raised its cost-effectiveness threshold for medicines for the first time in over 20 years. GlobalData examines the implications of this change for the innovative pharma sector, and for patient access to novel medicines in the UK.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
See what our customers are saying
Related reports
View more Product Type reports
New
New
New